H.C. Wainwright analyst Raghuram Selvaraju raised his price target for CorMedix to $3.50 and reiterates a Buy rating on the shares. The analyst continues to believe that it is possible that the FDA would agree to an accelerated filing pathway for Neutrolin because of the unmet nature of the medical need with respect to catheter-related bloodstream infections and the power of the previously-reported LOCK-IT-100 interim analysis. CorMedix management have indicated that progress continues to be made towards the finalization of a New Drug Application filing on Neutrolin, Selvaraju tells investors in a research note.

CorMedix announced DefenCath catheter lock solution is now commercially available for U.S. inpatient use. DefenCath is approved by the U.S. Food and Drug Administration to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. Joseph Todisco, Chief Executive Officer of CorMedix commented, "Today opens a new chapter for healthcare providers, offering them an opportunity to reduce the risk of CRBSIs in a patient population already vulnerable due to underlying kidney failure. We are proud to provide an option for adult patients who face the risk of CRBSIs. We look forward to expanding the availability of DefenCath to the outpatient setting later this year."